Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis.
Arya Mariam RoyChangchuan JiangStuthi PerimbetiLei DengCharles L ShapiroShipra GandhiPublished in: Cancers (2023)
Resectable HER2-low BC had a better prognosis than HER2-zero BC. Among those who received adjuvant chemotherapy in the higher oncotype RS group, those with HER2-low tumors had better survival.